AltruBio
Transforming lives through innovative antibody therapies.
San Francisco, United States · Founded 2020 · $288.0M raised
- Headquarters
- San Francisco, California
- Employees
- 11–50
- Founded
- 2020
- Business Model
- B2B
- Website
- altrubio.com
- Total Funding
- $288.0M
- Last Round
- $225.0M Series BMay 2024
- Rounds
- 2
About
Altrubio is a clinical-stage biopharmaceutical company developing novel antibody therapies targeting autoimmune and inflammatory diseases. Founded in 2020 and headquartered in South San Francisco, the company leverages proprietary antibody engineering platforms to create best-in-class therapeutics.
Summary
AltruBio is a Biotech company based in San Francisco, United States, founded in 2020. It has raised $288.0M in total across 2 rounds, most recently a $225.0M Series B round in May 2024. Investors include BVF Partners, aMoon and RA Capital Management.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
May 2024
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...